{"id":"W4392157493","doi":"10.1177/17562864231221331","title":"Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"National Health and Medical Research Council; Sanofi Genzyme; Grifols; Všeobecná Fakultní Nemocnice v Praze; Sanofi; European Commission; Canadian Institutes of Health Research; Multiple Sclerosis Australia; Teva Pharmaceutical Industries; Univerzita Karlova v Praze; Medical Research Council; Biogen; Celgene","keywords":"Natalizumab; Medicine; Multiple sclerosis; Disease; Fingolimod; First line therapy; Glatiramer acetate; Clinical significance; Teriflunomide; Intensive care medicine; Oncology; Internal medicine; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008440692,0.0001687045,0.0004643516,0.0003804514,0.0003012355,0.0004822449,0.0002229416,0.0003858621,0.0007091472],"category_scores_gemma":[0.002637924,0.0001936905,0.0006646509,0.0004173257,0.0002060225,0.000363506,0.0002957616,0.0004222709,0.0001130175],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003541406,"about_ca_system_score_gemma":0.0002499819,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001454323,"about_ca_topic_score_gemma":0.001264919,"domain_scores_codex":[0.999527,0.0001308723,0.00006805151,0.0001323724,0.00006773438,0.00007405777],"domain_scores_gemma":[0.9986032,0.0002266469,0.0007714292,0.0001044329,0.00006244629,0.0002319175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007067705,0.0002065802,0.9871209,0.0000245917,0.0004564792,0.0001274678,0.00007294108,0.0002568795,0.0006166917,0.00004228828,0.00008517437,0.003922225],"study_design_scores_gemma":[0.0004562381,0.003237971,0.9940546,0.00001668163,0.0004324542,0.0003593068,0.0001197968,0.00072598,0.0002524882,0.00007030078,0.0002636607,0.00001055385],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9996302,0.0002011553,0.00002593099,0.00001177955,0.000004047166,0.000005557227,0.00005423834,5.922233e-7,0.00006644255],"genre_scores_gemma":[0.9996592,0.00006987248,0.00002916065,0.00001698667,0.000008111385,0.000008115548,0.000164485,3.45273e-7,0.00004377703],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001454323,"threshold_uncertainty_score":0.004463971,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09250910395706537,"score_gpt":0.3612026078689723,"score_spread":0.268693503911907,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}